Real-World study examines Isavuconazole's effectiveness against deadly fungal infections
NCT ID NCT04550936
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at medical records of 307 adults in five European countries who were treated with the antifungal drug isavuconazole for serious fungal infections (invasive aspergillosis or mucormycosis). Researchers tracked how well the drug worked (clinical, radiological, and lab responses) and any side effects over 24 weeks. Since this was an observational study, patients received standard care as decided by their doctors, and no extra drugs were provided.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Isavuconazole (Cresemba)
What this could lead to
If the results confirm isavuconazole is effective and safe in routine care, it could reinforce its use as a treatment option for these serious fungal infections.
What could go wrong
This is an observational study, not a controlled trial, so it can't prove cause and effect. The results may be influenced by differences in patient care and underlying health conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCORMYCOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino
Turin, Piedmont, 10126, Italy
-
CHU de Limoges
Limoges, 87042, France
-
Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB2 0QQ, United Kingdom
-
Comprehensive Cancer Center Ulm (CCCU)
Ulm, 89081, Germany
-
Fundació Clínic Per A La Recerca Biomèdica
Barcelona, 08036, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, 39011, Spain
-
Institut de Cancérologie
Strasbourg, 67033, France
-
King'S College Hospital Nhs Foundation Trust
London, SE5 9RS, United Kingdom
-
Klinikum rechts der Isar Technische Universität München
Munich, 81675, Germany
-
Paris University
Paris, 75015, France
-
University Hospital Miguel Servet
Zaragoza, 50009, Spain
-
University Hospital of Cologne
Cologne, 50937, Germany
-
Universitätsklinik Frankfurt
Frankfurt, 60590, Germany
-
Vall d'Hebron University Hospital
Barcelona, 08035, Spain